

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 54515

**Manuscript Type:** ORIGINAL ARTICLE

*Retrospective Cohort Study*

**Vedolizumab for Ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford**

Samba Siva Reddy Pulusu<sup>1</sup>, Ashish Srinivasan<sup>2</sup>, Krupa Krishnaprasad<sup>3</sup>, Daniel Cheng<sup>4</sup>, Jakob Begun<sup>4</sup>, Charlotte Keung<sup>5</sup>, Daniel Van Langenberg<sup>5</sup>, Lena Thin<sup>6</sup>, Tamara Mogilevski<sup>7</sup>, Peter De Cruz<sup>7</sup>, Graham Radford-Smith<sup>3</sup>, Emma Flanagan<sup>8</sup>, Sally Bell<sup>8</sup>, Soleiman Kashkooli<sup>9</sup>, Miles Sparrow<sup>10</sup>, Simon Ghaly<sup>11</sup>, Peter Bampton<sup>12</sup>, Elise Sawyer<sup>13</sup>, Susan Connor<sup>13</sup>, Quart-UI-Ain Rizvi<sup>14</sup>, Jane M Andrews<sup>14</sup>, Gillian Mahy<sup>15</sup>, Paola Chivers<sup>16</sup>, Simon Travis<sup>2</sup>, Ian Craig Laurence<sup>1,17</sup>

## Match Overview

- | Match Number | Source   | Words   | Similarity |
|--------------|----------|---|------------|
| 1            | Internet | 59 words<br>crawled on 08-Apr-2019<br><a href="http://academic.oup.com">academic.oup.com</a>        | 1%         |
| 2            | Crossref | 59 words<br>"Inflammatory Bowel Disease Clinical", Journal of Gastroenterology and Hepatology, 2017 | 1%         |



ALL

IMAGES

VIDEOS

26,800 Results

Any time ▼

## Effectiveness and safety of vedolizumab in inflammatory ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049246>

Jan 07, 2020 · However, there is a paucity of data exploring the **outcomes** of **vedolizumab** in this group. Our objective was to determine the **clinical effectiveness and safety** of **vedolizumab** in older IBD patients within a **real-world multicenter UK cohort**.

**Author:** Hajir Ibraheim, Hajir Ibraheim, Mark ... **Publish Year:** 2020

## P571 Vedolizumab (VDZ) real-world outcomes in ulcerative ...

[https://academic.oup.com/ecco-jcc/article/12/supplement\\_1/S395/4807936](https://academic.oup.com/ecco-jcc/article/12/supplement_1/S395/4807936) ▼

Jan 16, 2018 · AbstractBackground. In GEMINI 1, UC response to **vedolizumab** (VDZ) was 47% at Week 6 and 42% by Week 52. Our aim was to assess **real-life outcomes** for VDZ in UC.

**Author:** S S R Pulusu, A Srinivasan, K Krishn... **Publish Year:** 2018

## Vedolizumab in IBD—Lessons From Real-world Experience; A ...

<https://academic.oup.com/ecco-jcc/article/12/2/245/4565692> ▼

Oct 25, 2017 · **Vedolizumab** [VDZ] is an anti-integrin monoclonal antibody effective in **ulcerative colitis** [UC] and **Crohn's disease** [CD]. Several **real-world experience** [RWE] studies with **VDZ** have been published to date. The aim of this systematic review was to summarise the available **real-life** experience with **VDZ**.

**Cited by:** 63 **Author:** Tal Engel, Bella Ungar, Diana E Yung, Sh...

**Publish Year:** 2018

## Vedolizumab for the treatment of ulcerative colitis ...

[https://www.researchgate.net/publication/284277871\\_Vedolizumab\\_for\\_the\\_treatment\\_of...](https://www.researchgate.net/publication/284277871_Vedolizumab_for_the_treatment_of...)

**Vedolizumab** (VDZ) demonstrated efficacy in **Crohn's disease** (CD) and **ulcerative colitis** (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of **VDZ** at week 14 in inflammatory **bowel disease** in a **multicenter** cohort of patients.





Vedolizumab for ulcerative colitis: Real world outcomes from a multicent



Sign in



ALL IMAGES VIDEOS

30,200 Results Any time ▾

## Vedolizumab for Ulcerative Colitis: Treatment Outcomes ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445254>

In this large **real-world cohort** we observed that VDZ was well tolerated and effective in achieving key clinical **outcomes**. INTRODUCTION. **Ulcerative colitis** (UC) is a chronic inflammatory disorder of the colon, characterized by bloody diarrhea, urgency, and abdominal pain. ... a prospective **multicenter observational** study.

**Cited by:** 34 **Author:** Neeraj Narula, Neeraj Narula, Farhad Pe...  
**Publish Year:** 2018

## Real-world Effectiveness and Safety of Vedolizumab for the ...

<https://academic.oup.com/ecco-jcc/article/13/9/1111/5320521> ▾

Feb 14, 2019 · Vedolizumab is a human monoclonal antibody that targets α4β7 integrin and blocks lymphocyte trafficking to the gut via the MADCAM pathway. 6 Following the phase 3 GEMINI trials, that demonstrated **efficacy in induction and maintenance of clinical remission** in both ulcerative colitis [UC] and **Crohn's disease** [CD], vedolizumab was approved as the first gut-selective biologic for the ...

**Cited by:** 6 **Author:** N Plevris, C S Chuah, R M Allen, I D Arn...  
**Publish Year:** 2019

## Search Tools

Turn off Hover Translation (关闭取词)





Background: **Vedolizumab** (VDZ) is effective for treatment of **ulcerative colitis** (UC) and Crohn's disease (CD). In GEMINI trials, anti-tumor necrosis factor (anti-TNF)-naïve patients had a superior